Purchase this article with an account.
E. Aydin, G.A. Peyman, M. Riazi Esfahani, A.A. Kazi, D.R. Sanders; Inhibition of Experimental Angiogenesis of Cornea by Doxycycline . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4481.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the effect of topically administered doxycycline on experimental corneal neovascularization in rats. Methods: Chemical cauterization of cornea in 36 eyes of 36 Long Evans male rats was performed using silver nitrate/potassium nitrate sticks. The animals were anesthetized and treated in accordance with the ARVO statement on the use of animals in ophthalmic and visual research. Topical instillation of doxycycline at 0.05% (pH: 3.3), 0.1% (pH: 3.1), 1% (pH: 2.3), 2% (pH: 2.1), 2% (pH neutralized to 7.4), and normal saline continued for 7 days. The percentage area of the cornea covered by neovascularization and scar in each group was calculated separately using computer software on digital photographs. All corneas in the experimental and control groups were evaluated histopathologically. Results: The means of percent area of corneal neovascularization were determined in eyes given doxycycline: 0.05%, 69.8 ± 18.0%; 0.1%, 64.5 ± 14.0%; 1%, 56.4 ± 20.8%; 2%, 54.8 ± 6.0%; and 2% (pH neutralized), 36.2 ± 4.3%; this measurement in the control group was 69.4 ± 5.7%. The mean of percent area of neovascularization in the 2% doxycycline (pH neutralized) group was significantly less than the control group and the <1% doxycycline group concentrations (p < 0.05). The percent corneal neovascularization in the 2% (pH neutralized) doxycycline group was not significantly different than in the 1% and 2% doxycycline groups (p < 0.05). There was no significant difference in percent area of corneal scar between control and study groups (p > 0.05). Conclusions: Topically administered 2% (pH neutralized) doxycycline has antiangiogenic effects, which contributed to significant suppression on corneal neovascularization. This drug may be therapeutically beneficial in treatment of corneal neovascularization in clinical trials.
This PDF is available to Subscribers Only